ViroGates announces first new ambulance study together with Nordic hospital partners starting May 2015
In May 2015 the Swedish Medical University Karolinska Institutet, Stockholm South General Hospital/ Södersjukhuset, KI SÖS, and Helsinki University Central Hospital, HUCH, supported by ViroGates will initiate a pivotal ambulance study to explore the use of suPARnostic® in a new method for prehospital patient assessment.
The ambulance study is aiming at testing 500 patients with suPARnostic®.
The study will affect 65 ambulances in the Stockholm area and around 25 ambulances in the Helsinki area over a period of 6-9 months.
ViroGates has announced the appointment of Lars Kongsbak and Bernd Uder as new members of the Board of Directors, together with Jørgen Thorball.
Lars Kongsbak, president & CEO of Exiqon A/S, will serve as chairman. Bernd Uder, formerly Senior Vice President and Managing Director at QIAGEN, joined the board as non-executive director. Jørgen Thorball is co-founder of ViroGates and formerly Chairman of the Board since 2001.